Tick-borne spirochetal infection (Borrelia burgdorferi) with characteristic erythema migrans and potential cardiac, neurologic, and arthritic complications.
Also known as: Lyme, Borrelia burgdorferi, borreliosis, erythema migrans, EM rash
Overview
Multisystem infection caused by Borrelia burgdorferi (US) and B. afzelii/B. garinii (Europe), transmitted by Ixodes scapularis (Northeast/Midwest US) and I. pacificus (West Coast) ticks. Course typically divided into early localized, early disseminated, and late disease.
Epidemiology
Most commonly reported vector-borne illness in the US (~30,000-40,000 reported cases yearly; CDC estimates true incidence ~476,000). Concentrated in Northeast, mid-Atlantic, upper Midwest, and Pacific Northwest. Peak incidence late spring through early fall.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Lyme Disease outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Outdoor exposure in endemic regions (hiking, gardening, hunting)
Tick attachment >36-48 hours (transmission rare with shorter attachment)
Age extremes (children 5-14, adults 50-69)
Pathophysiology
Spirochete enters skin during tick feeding, replicates locally producing erythema migrans, then disseminates hematogenously and via tissue migration to skin, joints, heart, and nervous system. Outer surface proteins (Osp) mediate immune evasion. Late arthritis driven by persistent inflammation and possible autoimmune mimicry; post-treatment Lyme disease syndrome remains incompletely understood.
Clinical presentation
Symptoms
Early localized (3-30 days post-bite): erythema migrans — expanding erythematous macule/patch, often with central clearing; ~70-80% of cases; flu-like symptoms (fatigue, myalgia, headache, low-grade fever)
Early disseminated (weeks-months): multiple secondary EM lesions, facial nerve palsy (often bilateral), lymphocytic meningitis, AV block (1st-3rd degree), myocarditis, migratory arthralgias
Late (months-years): monoarticular or oligoarticular arthritis (knee most common, large effusion), chronic neuroborreliosis (rare in US; encephalopathy, polyneuropathy), acrodermatitis chronica atrophicans (Europe)
Signs / physical exam
EM lesion >5 cm diameter, often warm but not particularly tender or pruritic
Facial droop (CN VII palsy), often bilateral — a key clue
Cardiac: variable AV block, sometimes requiring temporary pacing; usually resolves
Joint: large warm effusion (knee) with mild pain disproportionate to swelling
Classic findings
An expanding annular erythematous lesion >5 cm in an endemic area after summer tick exposure is sufficient for clinical diagnosis without serology.
Differential diagnosis
Southern tick-associated rash illness (STARI) — Lone star tick (Amblyomma americanum) bite in the Southeast; annular rash resembling EM but no Borrelia recovered; doxycycline empirically
Cellulitis — More tender, warm, sharply demarcated; lacks central clearing; rapidly progressive; treat for strep/staph
Tinea corporis — Scaling raised border, KOH positive; slower expansion
Erythema multiforme — Target lesions on extremities; mucosal involvement; HSV or drug trigger
Granuloma annulare — Chronic, non-tender annular plaques on dorsa of hands/feet; no exposure history
Septic arthritis — Acute monoarticular, very high WBC on arthrocentesis (>50,000); positive Gram stain/culture
Reactive arthritis — Post-GI/GU infection; conjunctivitis, urethritis, oligoarthritis; HLA-B27 association
Diagnostic workup
Diagnostic criteria
Clinical diagnosis based on EM in endemic exposure setting; otherwise two-tier serology required. Lyme arthritis: positive IgG Western blot virtually always present.
Labs
Two-tier serology (CDC): screening EIA → reflex Western blot (IgM if <30 days, IgG if >30 days); or modified two-tier with two EIAs (FDA cleared 2019)
Serology not indicated for isolated EM — treat clinically (antibodies often negative early)
Lyme PCR or culture from skin biopsy/synovial fluid — used selectively
CSF Lyme antibody index for suspected neuroborreliosis
Imaging
ECG if cardiac symptoms or high-risk exposure with constitutional symptoms
Joint ultrasound or MRI for effusion characterization if needed
Echo if myocarditis suspected
Diagnostic algorithm
Stage
Timing
Features
Treatment
Early localized
3-30 days
Single EM, flu-like symptoms
Doxycycline x 10 days
Early disseminated
Weeks-months
Multiple EM, CN VII palsy, AV block, meningitis
Doxycycline x 14-21 days; ceftriaxone if severe
Late
Months-years
Mono/oligoarthritis (knee), encephalopathy
Doxycycline x 28 days; ceftriaxone if refractory
Clinical stages of Lyme disease with corresponding antibiotic regimens.
Treatment
First-line
Doxycycline 100 mg PO BID — preferred for early localized and most early disseminated disease (also covers anaplasmosis, common coinfection)
Doxycycline now considered safe in children <8 for short courses (<21 days; AAP)
Duration: 10 days for EM, 14 days for early neurologic/cardiac, 28 days for Lyme arthritis
Amoxicillin 500 mg PO TID or cefuroxime axetil 500 mg PO BID — alternatives if doxycycline contraindicated (e.g., pregnancy)
IV ceftriaxone 2 g daily for meningitis, encephalopathy, or high-grade AV block (PR >300 ms or symptomatic)
Tick bite prophylaxis
Single 200 mg doxycycline dose if all met: identified Ixodes scapularis, attached ≥36 h, prophylaxis within 72 h of removal, endemic area with local infection rate ≥20%, doxycycline not contraindicated
Pregnancy
Amoxicillin or cefuroxime; doxycycline traditionally avoided in pregnancy
No congenital Lyme syndrome established; treat as in non-pregnant adults otherwise
Second-line / adjunct
Azithromycin or clarithromycin — less effective; reserve for true beta-lactam and tetracycline contraindications
Persistent arthritis after 28 days of oral therapy → second 28-day oral course or IV ceftriaxone 14-28 days
Cranial neuritis (especially bilateral CN VII), radiculoneuritis (Bannwarth syndrome — more common in Europe)
Post-treatment Lyme disease syndrome (PTLDS): persistent fatigue, arthralgia, cognitive symptoms >6 months; extended antibiotics not beneficial in randomized trials
PANCE pearls
Do NOT order serology in a patient with classic EM in an endemic area — treat clinically and avoid false negatives.
Bilateral facial palsy in a young adult in summer = Lyme until proven otherwise.
Coinfections (anaplasmosis, babesiosis) share Ixodes vector — consider in patients with cytopenias, hemolysis, or persistent fever on doxycycline (babesia not covered).
Lyme arthritis is monoarticular/oligoarticular and presents weeks to months later — large knee effusion with surprisingly little pain.
Single-dose doxycycline prophylaxis is the only validated tick-bite prophylaxis.
References
IDSA/AAN/ACR 2020 — Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease (Lantos et al., Clin Infect Dis 2021)
CDC 2019 — Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease (MMWR)
AAP — Red Book: Tetracycline use in children <8 for short courses
Practice Infectious Disease questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.